Signet Health

CELL AND GENE THERAPY

SQZ Biotechnologies | July 13, 2022

SQZ Biotechnologies Company focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced the publication of a technical review examining the ability of SQZ® Antigen Presenting Cells to activate CD8 T cells through MHC-I antigen presentation, an approach that may enable a more powerful T cell response and infiltration into solid tumors. Published in ESMO’s Immuno-Oncology and Technology journal, the review further explores the advantages of t...

BioSpace | February 20, 2020

Bladder cancer drug Padcev, which was approved by the U.S. Food and Drug Administration in December, secured Breakthrough Therapy designation for the treatment of patients with another type of bladder cancer. Seattle Genetics and Astellas Pharma, the co-developers of Padcev (enfortumab vedotin-ejfv) said the new designation was awarded to the bladder cancer drug in combination with Merck’s checkpoint inhibitor Keytruda for the treatment of patients with unresectable locally advanced or met...

RESEARCH

Quantgene | June 08, 2021

Quantgene, biotechnology, cloud, and AI company located in Santa Monica, CA, and Berlin, Germany, has demonstrated the most exact gene sequencing yet published in the industry, as shown in the February edition of GENES, a major scientific journal in medical genomics. "Precision Genomics is revolutionizing medicine, but it is being hampered by a lack of rapid, accurate, and easily accessible technology," said Jo Bhakdi, CEO of Quantgene. "Today, the protection of hum...

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

ImmunoGen, Inc. | March 02, 2023

On March 1, 2023, ImmunoGen, Inc., a leading firm specializing in antibody-drug conjugates (ADCs), announced a global, multi-target license and option agreement with Vertex Pharmaceuticals. The deal provides Vertex with the rights to use ImmunoGen's ADC technology to research and discover targeted conditioning agents to be used in gene editing. After each research period, Vertex will have the option to obtain an exclusive worldwide license to research, develop, and commercia...